絞り込み

16426

広告

奄美ノネコ捕獲計画案、1週間期限譲渡先探す - 読売新聞

読売新聞奄美ノネコ捕獲計画案、1週間期限譲渡先探す読売新聞世界自然遺産登録を目指す奄美大島で野生化したネコ(ノネコ)が固有種を襲っている問題で、環境省と鹿児島県...

  1. 福島第1、屋根カバー設置を完了 (デイリ...
  2. Tesla、パブリッククラウド環境に不正...
  3. どうなる、地球温暖化時代の「冬季五輪」 ...
  4. [企業] Ionis 腎疾患治療アンチセ...

ニュース一覧

Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility.

著者 Takahashi N , Take Y
J Pharmacol Exp Ther.2017 Nov 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (139view , 0users)

Full Text Sources

Tegoprazan, (S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-carboxamide, a potassium-competitive acid blocker (P-CAB), is a novel potent and highly selective inhibitor of gastric H+/K+-ATPase. Tegoprazan inhibited porcine, canine, and human H+/K+-ATPases in vitro with IC50 values ranging 0.29 ~ 0.52 μM while that for canine kidney Na+/K+-ATPase was more than 100 μM. A kinetic analysis revealed that tegoprazan inhibited H+/K+-ATPase with potassium-competitive manner and the binding was reversible. Oral single administrations of tegoprazan ranging 0.3 ~ 30 mg/kg in dogs were well absorbed into blood stream and distributed in gastric tissue/fluid higher than in plasma. Tegoprazan potently inhibited histamine-induced gastric acid secretion in dogs and a complete inhibition was observed at 1.0 mg/kg starting from 1 hr after administration. Moreover, an oral administration of tegoprazan at 1 and 3 mg/kg reversed the pentagastrin-induced acidified gastric pH to the neutral range. Interestingly, 3 mg/kg tegoprazan immediately evoked a gastric phase III contraction of migrating motor complex (MMC) in pentagastrin-treated dogs and similar effects was observed with the other P-CAB, vonoprazan.  Tegoprazan is the novel P-CAB which may provide a new option for the therapy of gastric acid-related and motility-impaired diseases.
PMID: 29180359 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード